Special Issue

Advances in Bone Metabolism, Bone Homeostasis and Osteogenesis

Message from the Guest Editors

Healthy bone is maintained by continuous bone remodeling, a dynamic process of bone matrix deposition and resorption during development and homeostasis. This process is tightly regulated by the coordinated action of multiple bone cells. While these cells are responsible for repairing microdamage and replacing aged bone, their functions are affected by circulating factors. Conversely, research over the past several years has demonstrated that bone also acts as an important endocrine organ by secreting peptides or steroid hormones to affect other organs and ultimately regulate whole body energy metabolism.

Understanding the mechanisms by which bone-derived factors affect systemic metabolic functions, and how circulating endocrine factors affect bone homeostasis and osteogenesis, will provide valuable insight for developing novel therapeutic strategies to treat metabolic bone diseases.

This Special Issue will provide an overview of recent advances in bone metabolism, bone homeostasis, and osteogenesis. In particular, it will highlight the impact of metabolic factors on bone remodeling, cellular crosstalk in bone homeostasis, and novel therapeutic targets for bone disorders.

Guest Editors

Dr. Youngjae Jeong

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA

Dr. Laura Ortinau

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA

Deadline for manuscript submissions

31 March 2026

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/252877

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).